Filtered By:
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 1499 results found since Jan 2013.

Hypertension - human studies
Conclusions:Higher predialysis SBP variability is associated with stroke on HD populations suggesting a potential role for cerebral perfusion instability. We confirm known associations between age, diabetes, pre-existent cerebrovascular disease and hypertension. In contrast to studies in non-dialysis patients we do not find an association between EPO dose and stroke. Interventional trials of blood pressure management on stroke are recommended.
Source: Nephrology Dialysis Transplantation - May 10, 2013 Category: Urology & Nephrology Authors: Power, A., Duncan, N., Pusey, C., Usvyat, L., Marcelli, D., Marelli, C., Kotanko, P., MONDO Consortium, Li, Z., Wang, J., Yuan, X., Wang, J., Wang, L., Ozkayar, N., Altun, B., Yildirim, T., Yilmaz, R., Dede, F., Hayran, M., Arici, M., Aki, T., Erdem, Y., Tags: Abstracts Source Type: research

Progeria syndrome in CKD/ESRD
Conclusions: Renal impairment independently associates with greater stroke disability at presentation and worse functional outcomes despite modern stroke care. Nonetheless these patients are also less likely to be thrombolysed for acute ischaemic stroke, which suggests a possible inequity in access to healthcare that requires urgent study.
Source: Nephrology Dialysis Transplantation - May 10, 2013 Category: Urology & Nephrology Authors: Power, A., Gill, D., Wietek, N., Lim, J., Tanna, R., Duncan, N., Troyano Suarez, N., Del Nogal Avila, M., Mora Valenciano, I., Olmos Centenero, G., Diez-Marques, M. L., Cortes, M., Lopez Ongil, S., Martin Sanchez, P., Rodriguez Puyol, D., Ruiz Torres, M. Tags: Abstracts Source Type: research

Can I use DOAC in a patient with renal disease?
Case A 76-year-old man is diagnosed with non-valvular atrial fibrillation. His comorbid conditions are hypertension, diabetes complicated by neuropathy, and chronic kidney disease stage 3. His current medications include metformin, lisinopril, gabapentin, and aspirin. His most recent laboratories showed a creatinine 1.8, creatinine clearance (CrCl) 35 mL/min, hemoglobin 11g/dL, and international normalized ratio 1.0. His congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, and sex (CHADSVASc) score is 4. Which medication should we use to prevent stroke in this patient?  Brief overview of the is...
Source: The Hospitalist - February 3, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: Renal & Genitourinary Source Type: research

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation: A Meta-Analysis of Observational Studies
The objective of this study was to assess the effectiveness and safety of warfarin use in patients with AF undergoing dialysis. Three databases PubMed, EMBASE, and OVID were searched from their inception to August 2015. Observational studies which assessed the ischemic stroke or bleeding risk of warfarin use in dialysis patients with AF were included. Two reviewers independently extracted data and assessed methodological quality based on the Newcastle–Ottawa Scale score. Combined hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using the random-effects model and heterogeneity was assessed based...
Source: Medicine - December 1, 2015 Category: Internal Medicine Tags: Research Article: Meta-Analysis of Observational Studies in Epidemiology Source Type: research

Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry
Abstract Atrial fibrillation (AF) is common in dialysis patients. However, clinical characteristics and outcomes of dialysis patients with AF are poorly understood. The Fushimi AF Registry is a community-based prospective survey of AF patients in Japan. Follow-up data were available for 3713 patients with a median follow-up of 2.8 years. We compared clinical characteristics and outcomes between the dialysis group (n = 92; 2.5 %) and others. The dialysis group had more various co-morbidities, with a mean CHADS2 score of 2.5, and the rate of warfarin prescription was 38 %. The annual incidence rates of stroke ...
Source: Heart and Vessels - March 14, 2016 Category: Cardiology Source Type: research

Renal transplantation delays major adverse cardiac events (MACEs) in  patients with end-stage renal disease: A nationwide population-based study
Conclusion RT seemed not to reduce the risk of MACEs directly, but it could have dramatically delayed MACEs and stroke episodes in the ESRD patients. Furthermore, a lower mortality rate was observed in the ESRD patients who received RT than in those undergoing chronic dialysis. Further in-depth investigation is necessary to identify other protective factors against MACEs or stroke in ESRD.
Source: Journal of the Chinese Medical Association - July 1, 2018 Category: General Medicine Source Type: research

Renal transplantation delays major adverse cardiac events (MACEs) in patients with end-stage renal disease: A nationwide population-based study
ConclusionRT seemed not to reduce the risk of MACEs directly, but it could have dramatically delayed MACEs and stroke episodes in the ESRD patients. Furthermore, a lower mortality rate was observed in the ESRD patients who received RT than in those undergoing chronic dialysis. Further in-depth investigation is necessary to identify other protective factors against MACEs or stroke in ESRD.
Source: Journal of the Chinese Medical Association - July 5, 2018 Category: General Medicine Source Type: research

Patients at elevated risk of major adverse events following endarterectomy for asymptomatic carotid stenosis
Conclusions A high-risk subset of patients undergoing CEA for asymptomatic carotid stenosis can be identified. If patient selection is optimized and perioperative morbidity and mortality are minimized, CEA will continue to play an important role in stroke prevention for those with significant asymptomatic carotid stenosis.
Source: The American Journal of Surgery - May 23, 2015 Category: Surgery Source Type: research

New aspects of cerebrovascular diseases in dialysis patients.
Authors: Naganuma T, Takemoto Y Abstract Growing evidence suggests that chronic kidney disease is a significant risk factor for stroke, subclinical cerebrovascular abnormalities, and cognitive impairment, independent of known cardiovascular risk factors. Cerebrovascular disease is also a major cause of death in dialysis patients, who have a much higher incidence of stroke compared to the normal population. Strokes in dialysis patients are also characterized by a higher incidence of hypertensive intracerebral hemorrhage compared with those in the general population. Recent studies on dialysis cohorts have shown that...
Source: Contributions to Nephrology - June 1, 2015 Category: Urology & Nephrology Tags: Contrib Nephrol Source Type: research

Valvular calcification upon initiating dialysis predict the appearance of cardiovascular events in patient evolution.
CONCLUSIONS: The prevalence of VC at the commencement of dialysis is very high and its presence is an independent predictor of event and cardiovascular mortality presentation in the course of follow-up. PMID: 26300509 [PubMed - as supplied by publisher]
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - August 25, 2015 Category: Urology & Nephrology Tags: Nefrologia Source Type: research

Long-term effects of AST-120 on the progression and prognosis of pre-dialysis chronic kidney disease: a 5-year retrospective study
Abstract AST-120 has been used widely in Japan to slow the deterioration of renal function in patients with chronic kidney disease (CKD) by decreasing uremic toxins. The heart and the kidney are closely related, with cardiorenal interaction being very important. This retrospective study examined whether AST-120 influences the prevalence of dialysis induction, mortality, and cardiac and stroke events in CKD patients. The study included 278 patients diagnosed with chronic renal failure (CKD stage: III–V) in 2006. Of these patients, 128 received AST-120 (6 g/day), while the remaining 150 patients did not. A log-ra...
Source: Heart and Vessels - December 23, 2015 Category: Cardiology Source Type: research

A contemporary evaluation of carotid endarterectomy outcomes in patients with chronic kidney disease in the United States.
Conclusions Patients with ESRD undergoing CEA had an increased risk of respiratory and septic complications, but not a higher risk of stroke compared to patients with normal renal function. The greatest risks of postoperative stroke, respiratory, and cardiac complications were found in patients with CKD. A diagnosis of ESRD and CKD were both found to significantly increase hospital mortality, length of stay and cost. Where clinicians typically consider ESRD patients the highest risk for CEA, further consideration should be given to patients with CKD not yet on dialysis as they had the higher risk of cardiac complications a...
Source: Vascular - December 31, 2016 Category: Surgery Authors: Patel AR, Dombrovskiy VY, Vogel TR Tags: Vascular Source Type: research

Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States.
Conclusions -Among ESKD patients with AF on dialysis, apixaban use may be associated with lower risk of major bleeding compared with warfarin, with a standard 5 mg twice a day dose also associated with reductions in thromboembolic and mortality risk. PMID: 29954737 [PubMed - as supplied by publisher]
Source: Circulation - June 28, 2018 Category: Cardiology Authors: Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK Tags: Circulation Source Type: research